SHREVEPORT, La. - A new drug developed by Eli Lily works in a unique way compared to treatments already on the market, like Ozempic and Mounjaro.

It's called retatrutide, and what makes retatrutide different is that it targets not just one or two, but three hormone receptors in the pancreas: GLP-1, GIP, and glucagon. These are all naturally occurring hormones that play a big role in regulating blood sugar, appetite, and metabolism.

Drugs that activate the GLP-1 and GIP receptors, like Ozempic and Mounjaro or semaglutide and tirzepatide, help the body produce more insulin, allow cells to absorb more glucose, slow down digestion, and help people feel fuller, longer.

But retatrutide goes a step further by also activating the glucagon receptor and that's where things get even more interesti

See Full Page